Țară: Irlanda
Limbă: engleză
Sursă: HPRA (Health Products Regulatory Authority)
RIFAMPICIN
Sandoz GmbH
150mg Milligram
Capsule
1997-07-05
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Rimactane Capsules 150mg. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains Rifampicin 150mg. For list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Capsules, hard. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS In the treatment of tuberculosis and certain other mycobacterial infections. _Non-mycobacterial infections:_ In these infections, e.g. _staphylococcal _infections, Rimactane should only be employed: o if the pathogens are resistant to the first-line antibiotics that normally prove effective, o if the pathogens are demonstrably sensitive to rifampicin, o if given in combination with other antibiotics/chemotherapeutic agents to which the pathogens are sensitive, o if a diagnosis of tuberculosis or leprosy has first been excluded. _Prevention of meningococcal meningitis:_ Rimactane is also indicated for the chemoprophylaxis of _meningococcal meningitis._ 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _For the management of tuberculosis and certain opportunistic mycobacterial infections_: Rimactane must always be given in association with other anti-tuberculosis drugs, to prevent emergence of resistant strains. _Use in Adults_: 450-600mg daily as a single dose (based on approximately 10mg per kg body weight). (Those patients 50kg (8 stone) and over should take 600mg rifampicin daily, whilst patients under 50kg should take 450mg). IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 06/02/2009_ _CRN 2053449_ _page number: 1_ The following chemotherapeutic agents are employed today as combined therapy for tuberculosis: rifampicin (Rimactane) (RMP), isoniazid (INH), pyrazinamide (PZA), ethambutol (EMB), streptomycin (STM). The Citiți documentul complet